November 22, 2021
Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
November 18, 2021
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 8, 2021
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
Arcturus Therapeutics Partnerships
In October 2017, Arcturus entered into a partnership with Janssen, a Johnson & Johnson company, to develop and commercialize nucleic acid-based drug products for the treatment of specified diseases, including HBV, using Arcturus’ LUNAR® lipid-mediated delivery platform. Under the agreement, facilitated by J&J Innovation, Arcturus received an upfront cash payment and will receive R&D support, as well as pre-clinical, development, and sales milestone payments, and royalty payments on any future licensed product sales. Janssen will assume responsibility for development costs and all commercialization costs associated with the program.
In December 2016, Arcturus entered into a partnership with Takeda to develop RNA-based therapeutic candidates for the treatment of NASH and other GI-related disorders, utilizing Arcturus’ wholly owned therapeutic delivery platform, LUNAR®.
LUNAR-GSD3 and LUNAR-RARE
In October 2015, Arcturus has partnered with Ultragenyx Pharmaceutical, Inc. to develop RNA medicines that treat rare and ultra-rare diseases. This collaboration combines Arcturus’ expertise in RNA medicines with Ultragenyx’ proven ability in rare disease drug development. In this partnership, Arcturus is exploiting the versatility of our proprietary Lipid-enabled and Unlocked Nucleic Acid modified RNA (LUNAR®) lipid-mediated delivery platform to design and optimize mRNA medicines for rare disease targets. These medicines will be developed and commercialized by Ultragenyx.